Introduction
Background and rationale 6a Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention 1-3 6b Explanation for choice of comparators 3 Objectives 7 Specific objectives or hypotheses 3
Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) 3
Methods: Participants, interventions, and outcomes
Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained 3 
Methods: Assignment of interventions (for controlled trials)
Allocation:
Sequence generation 16a
Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions N.a.
Allocation concealment mechanism 16b
Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned N.a.
Implementation 16c
Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions n.a.
Blinding (masking) 17a
Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how n.a.
17b
If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial n.a.
Methods: Data collection, management, and analysis

Data collection methods 18a
Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol
6-8 18b
Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols n.a.
Data management 19
Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation) n.a.
Methods: Monitoring
Data monitoring 21a
Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed n.a.
21b
Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial n.a.
Harms 22
Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct n.a.
Auditing 23 Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor n.a.
Ethics and dissemination
Research ethics approval 24 Plans for seeking research ethics committee/institutional review board (REC/IRB) approval 6
Protocol amendments 25
Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators) n.a.
Consent or assent 26a
Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32) 6 26b Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable n.a.
Confidentiality 27
How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial n.a.
Declaration of interests 28
Financial and other competing interests for principal investigators for the overall trial and each study site 10
Access to data 29 Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators n.a.
Ancillary and posttrial care 30 Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation n.a.
Dissemination policy 31a
Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions n.a.
31b
Authorship eligibility guidelines and any intended use of professional writers n.a.
31c
Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code n.a.
Appendices
Informed consent materials 32
Model consent form and other related documentation given to participants and authorised surrogates n.a.
Biological specimens 33
Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable n.a.
*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "Attribution-NonCommercial-NoDerivs 3.0 Unported" license.
